Fiskus, Warren http://orcid.org/0000-0002-7343-6214
Boettcher, Steffen http://orcid.org/0000-0001-9937-0957
Daver, Naval http://orcid.org/0000-0001-7103-373X
Mill, Christopher P.
Sasaki, Koji http://orcid.org/0000-0002-9140-0610
Birdwell, Christine E.
Davis, John A.
Takahashi, Koichi http://orcid.org/0000-0002-8027-9659
Kadia, Tapan M. http://orcid.org/0000-0002-9892-9832
DiNardo, Courtney D.
Jin, Qi
Qi, Yuan
Su, Xiaoping
McGeehan, Gerard M.
Khoury, Joseph D. http://orcid.org/0000-0003-2621-3584
Ebert, Benjamin L. http://orcid.org/0000-0003-0197-5451
Bhalla, Kapil N. http://orcid.org/0000-0001-5209-5126
Article History
Received: 8 November 2021
Revised: 10 December 2021
Accepted: 16 December 2021
First Online: 11 January 2022
Competing interests
: Gerard M. McGeehan is an employee of Syndax Pharmaceuticals. Benjamin L. Ebert has received research funding from Celgene, Deerfield, Novartis, and Calico; and he is a member of the scientific advisory board and shareholder for Neomorph Therapeutics, Skyhawk Therapeutics, and Exo Therapeutics, none of which are directly related to the content of this paper. The remaining authors declare no competing interests.